Vector Clinical Trials — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$416,320	113
2024	Research	$182,606	6

Breakdown

Who paid Research payments · program years 2024–2025

Seqirus USA Inc $228,229 91 payments
Moderna TX, Inc. $183,528 8 payments
Amgen Inc. $150,111 4 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $20,031 3 payments
Vanda Pharmaceuticals Inc. $15,821 2 payments
Boehringer Ingelheim International GmbH $814 10 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $392 1 payment

Studies the money was for Research payments · program years 2024–2025

A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $222,236 87 payments
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $182,606 6 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $120,556 1 payment
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $21,237 14 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $16,513 1 payment
Evaluating the Effects of Tasimelteon VS. Placebo in Treating Pediatric Insomnia $15,821 2 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) $13,042 2 payments
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age $5,993 4 payments
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $922 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.